SCIENTIFIC REPORTS

OPEN

Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome

Yu Wang, Xin Fu, Jing Xu, Qihong Wang & Haixue Kuang

Received: 03 March 2016

Accepted: 26 May 2016

Published: 16 June 2016

Polycystic ovary syndrome (PCOS) is a common multifactorial endocrine disorder among women of childbearing age. PCOS has various and heterogeneous clinical features apart from its indefinite pathogenesis and mechanism. Clinical drugs for PCOS are multifarious because it only treats separate symptoms. Berberine is an isoquinoline plant alkaloid with numerous biological activities, and it was testified to improve some diseases related to PCOS in animal models and in humans. Systems pharmacology was utilized to predict the potential targets of berberine related to PCOS and the potential drug-drug interaction base on the disease network. In conclusion, berberine is a promising polypharmacological drug for treating PCOS, and for enhancing the efficacy of clinical drugs.

Polycystic ovary syndrome (PCOS) is an endocrine disorder characterized by anovulation, hyperandrogenism and polycystic ovaries in ultrasonic scanning, which affects proximate 5–15% in women of childbirth age^{1–6}.

The clinical manifestations of PCOS are heterogeneous and diversity in androgen excess (hyperandrogenemia, hirsutism, acne and alopecia), irregular menstrual cycle, infertility, insulin resistance and obesity. PCOS patients also have a high risk for the development of severe metabolic disorders, such as cardiovascular disease, type 2 diabetes, metabolic syndrome and endometrial cancer⁷.

The pathogenesis and mechanism of PCOS remain unclear. PCOS is currently considered as a mainly hyperandrogenic disorder⁸. Many PCOS patients are overweight or obese, and a mainly abdominal fat distribution is particularly common in these women^{9,10}. Insulin resistance has been implicated in the pathogenesis of anovulation and infertility in PCOS, and abnormalities in insulin action have been observed in a variety of reproductive tissues in PCOS women¹¹, 50–70% of patients with PCOS show insulin resistance and compensatory hyperinsulinism¹². Escobar proposed that a vicious circle has existed in PCOS women, that may start during their early stages of life or even in babyhood, whereby androgen excess favoring the abdominal deposition of fat further facilitates androgen secretion by the ovaries and adrenals in PCOS patients¹³.

Given its heterogeneous clinical manifestations, the treatment of PCOS is not unified, but instead depends on each phenotypic features and reproductive desire. Weight reduction and lifestyle modifications are highly recommended therapies that improve the metabolic status, ovulation regularity and protection of PCOS patients from cardiovascular diseases¹⁴, unless other issues indicate that drug or hormonal interventions are superior. So the drugs used in clinical treating for PCOS are numerous including combined oral contraceptives (COCs), antiandrogenic progestins, insulin-sensitizing drugs, and so forth. Generally, these drugs only treat the respective single phenotypic feature⁷.

Berberine is an isoquinoline plant alkaloid isolated from several plants such as *Hydrastis canadensis*, *Berberis vulgaris*, *Coptis chinensis* and *Berberis aristata*. Berberine has multiple pharmacological properties, including anti-microbial, glucose-lowering and cholesterol-lowering, anti-tumoral and immune-modulating activities¹⁵. Several studies show that berberine can increase glucose uptake and reduce insulin resistance *in vitro*^{16,17}. An increasing number of clinical studies also emphasize the positive role of berberine in treating PCOS^{18–22}. Berberine is a high-affinity substrate for P-glycoprotein (P-gp), organic cation transporters and some cytochrome P450 isoenzymes, which all have crucial roles in the transshipment and metabolism of drugs, so berberine was reported to increase the blood concentration of other drugs transferred by these pathways to enhance

Key Laboratory of Chinese Materia Medica (Ministry of Education), Heilongjiang University of Chinese Medicine, 150040, Harbin, P.R. China. Correspondence and requests for materials should be addressed to Q.W. (email: 2872144234@qq.com) or H.K. (email: hxkuang56@163.com)

Figure 1. Target-pathway network. The target-pathway network was constructed by linking the potential targets and their biological pathways. The nodes represent targets (orange diamonds) and pathways (blue octagon).

drug effect^{23–25}. Some clinical studies also began to evaluate the cooperation of berberine and other drug²⁶. To date, no serious adverse effects have been reported for BBR, apart from gastrointestinal side effects²⁷.

Systems pharmacology is defined as an approach to translational medicine that combines computational and experimental methods to elucidate, validate and apply new pharmacological concepts to the development and use of drugs²⁸. The previous computational methods for the identification of drug-target interactions depended on some single study such as target fishing, compound profiling, ligand similarity search^{29,30} and “omics” approach. In contrast to previous methods, systems pharmacology provides an integrated “systems-level” approach to determining mechanisms of action of drugs in animal models and in patients²⁸. Systems pharmacology is widely used in drug discovery, target prediction and mechanism research, especially in traditional herbal medicine^{31,32}. This article applies systems pharmacology to investigate the mechanism of berberine and its interaction with other clinical drugs in treating PCOS at the target level.

Results and Discussion

Candidate targets of PCOS screening and pathway-target network analysis. The targets were selected using our research strategy and verified in the UniProt database (<http://www.uniprot.org/>). A total of 130 candidate targets (Table S1) of PCOS were validated finally. After inputting these targets to Database for Annotation, Visualization and Integrated Discovery (DAVID) database, 84 targets were enriched to 13 Kyoto Encyclopedia of Genes and Genomes (KEGG) biological pathways and results were shown in Table S2. Six biological pathways including neuroactive ligand-receptor interaction (NLI), adipocytokine signaling pathway (ASP), insulin signaling pathway (ISP), PPAR signaling pathway (PSP), type II diabetes mellitus (TDM) and steroid hormone biosynthesis (SHB) show extreme significant P value ($P < 0.002$). NLI demonstrates various interactions between the ligands and receptors, and the endometrial gene expression altering among PCOS patients is related to NLI as reported in clinical study³³. ASP and PSP are correlated with leptin and adiponectin production, which regulates fatty acid oxidation and glucose uptake. ISP and TDM are related to insulin resistance; SHB is involved in biosynthesis of androgens, estrogens, progesterones and glucocorticoids. The six pathways cover all three main potential mechanisms including sex hormones disorder, insulin resistance and abnormal lipid metabolism.

To decipher the potential mechanism and potential significant targets of PCOS, a pathway-target network was constructed based on potential targets and their acting pathways. As shown in Fig. 1, the pathway-target network contains 97 nodes (13 pathways and 84 potential targets) and 130 edges. The mean degree value (the number of the target associated with it) of biological pathways was 10. The degree of NLI, ASP, ISP and PSP are 44, 12, 12 and 9; the betweenness centrality of NLI, SHB and ASP is 0.71, 0.67 and 0.51, that are the top-ranks in pathway-target network respectively. It described the importance of these pathways. Additionally, the results indicate that some targets have been hit by multiple pathways in the pathway-target network. Mitogen-activated

Figure 2. ClueGO analysis of the candidate targets. Functionally grouped network of enriched categories was generated for the target genes. GO terms are represented as nodes, and the node size represents the term enrichment significance. The node pie charts represent the molecular function and reactome analysis of these targets. Only the most significant term in the group was labeled. (A) Representative molecular function interactions among candidate targets. (B) Representative reactome analysis interactions among candidate targets.

protein kinase 8 (MAPK8), mitogen-activated protein kinase 9 (MAPK9), tumor necrosis factor (TNF) and mitogen-activated protein kinase 14 (MAPK14) are linked by 6, 6, 5 and 3 pathways. Given their important positions in the pathway-target network, the MAPK family (MAPK8, MAPK9 and MAPK14) may be the key targets in PCOS mechanism. The MAPKs are mediators of signal transduction from the cytosol to the nucleus³⁴, which is involved in androgen biosynthesis and insulin resistance in PCOS^{35,36}.

As a widely used Cytoscape plugin, ClueGO³⁷ was used to further identify the biological functions of these 130 potential targets in biological networks. As shown in Fig. 2, the results were divided into two strata: molecular functions and the reactome analysis. Specially, the molecular functions were mainly consisted of five groups: signaling receptor activity, adrenergic receptor activity, steroid dehydrogenase activity, peptide receptor activity, steroid hormone receptor activity, peptide binding, G-protein coupled amine receptor activity and monocarboxylic acid binding, which indicated that most potential targets were related to signaling receptor activity, peptide receptor activity and peptide binding (Fig. 2A). The reactome of the targets were mainly related to activation of nuclear signaling ERBB4, metabolism of lipids and lipoproteins, GPCR ligand binding, fatty acid, triacylglycerol, and ketone body metabolism, intergration of energy metabolism and signaling by retinoic acid (Fig. 2B). Finally, we found that most of the targets were related to the activation of GPCR ligand binding, metabolism of lipids and lipoproteins and fatty acid, triacylglycerol, and ketone body metabolism. These biological functions have been linked to material transmembrane transport, lipids metabolism and hormone metabolism.

Finding known drug targets and potential protein targets of berberine. In the similar manner, we identified 30 clinical drugs for treating PCOS 30 drugs for treating PCOS from the network database and literatures. These drugs include four combined oral contraceptives (COCs), seven antiandrogenic progestins, four antiandrogens, five insulin-sensitizing drugs, three statins, two aromatase inhibitors and five other drugs (Table 1). COCs demonstrate hormonal action at central and peripheral levels simultaneously: suppressing the luteinizing hormone release and subsequently decrease ovarian androgen production; increasing the liver's production of sex hormone binding protein, which decreases the free androgens in plasma³⁸. The reduced androgen synthesis and the peripheral block of androgen receptors represents additional activities acting on hyperandrogenism³⁹. The efficacy of antiandrogenic progestins is due to antagonize androgen receptor or inhibit 5 α -reductase activity to reduce androgen level³⁸. Antiandrogens are the most effective drugs currently available for androgen excess by blocking androgen receptor blockers or inhibiting 5 α -reductase given the mechanism of action⁴⁰. Insulin-sensitizing drugs act by improving insulin sensitivity to compete with insulin resistance and subsequently prevent cardiovascular disease and type 2 diabetes. Statins benefit in PCOS patients by improving chronic inflammation and lipids metabolism, androgen excess, oxidative stress and metabolic parameters⁴¹. Aromatase inhibitors block the conversion of testosterone and androstenedione to estradiol and estrone, respectively. The decrease of estrogens activity releases the hypothalamus via negative feedback, allowing for the release of follicle-stimulating hormone and luteinizing hormone⁴². From the results of DrugBank database, 25 drugs obtained 17 targets related to PCOS. Therefore, most of the currently available clinical drugs for treating PCOS can only affect limited number of targets current clinical.

Class	Drug name
COCs	Progesterone
	Estradiol
	Levonorgestrel
	Medroxyprogesterone Acetate
Antiandrogenic progestins	Cyproterone acetate
	Drospirenone
	Dienogest
	Chlormadinone acetate
	Desogestrel
	Gestodene
	Norgestimate
Antiandrogens	flutamide
	Spironolactone
	Finasteride
	Ketoconazole
Insulin-sensitizing drugs	Metformin
	Pioglitazone
	Rosiglitazone
	Liraglutide
	Myo-Inositol
Statins	Atorvastatin
	Rosuvastatin
	Simvastatin
Aromatase inhibitors	letrozole
	anastrozole
Other drugs	Eflornithine
	Clomifene
	Dexamethasone
	Leuprolide
	Triptorelin

Table 1. The clinical drugs for PCOS treatment.

Fifteen PCOS-related potential protein receptors of berberine were identified by contrasting and merging the results from PharmMapper and the TCMSP database with the PCOS candidate targets. The targets were shown in Table 2 with PharmMapper Fit score respectively. These targets can be divided into three categories based on their functions. Androgen receptor (AR), estrogen receptor (ESR1) and progesterone receptor (PGR) are nuclear hormone receptors that are directly involved in biosynthesis and conversion of androgens. Retinoic acid receptors (retinoic acid receptor RXR-alpha (RARA) and retinoic acid receptor gamma (RARG)) are also related to androgen biosynthesis⁴³. Aldo-keto reductase family 1 member C3 (AKR1C3) can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Insulin receptor (INSR) and dipeptidyl peptidase 4 (DPP4) are involved in insulin resistance, in which DPP4 is a novel emerging target against hyperglycemia⁴⁴. Glucocorticoid receptor (NR3C1), corticosteroid 11-beta-dehydrogenase isozyme 1 (HSD11B1) and methionine aminopeptidase 2 (METAP2) are linked to lipid metabolism^{45,46}. Tyrosine-protein phosphatase non-receptor type 1 (PTPN1), thyroid hormone receptor beta (THRB) and beta-2 adrenergic receptor (ADRB2) are simultaneously implicated with insulin resistance and obesity^{47–49}, and MAPK14 acts on androgen biosynthesis and insulin resistance as previously mentioned.

Molecular docking. To confirm the valid bonding effects between berberine and its predicted targets, molecular docking was evaluated using the berberine-target binding energy with the clinical drug-target binding energy acting as contrast. Additionally some studies suggest that AMP-activated protein kinase (AMPK) plays a central role in pathways which berberine modulates cellular processes⁵⁰, so we also selected three subunit proteins from AMPK family including AMPKA1, AMPKA2 and AMPKB1 (PDB ID: 4RED, 2H6D and 4CFE) to measure the combination ability with berberine using AutoDock Vina. AMPK is a cellular energy sensor that, upon activation, stimulates catabolic processes (such as fatty acid oxidation, glucose uptake, lipolysis) while inhibits anabolic processes (such as gluconeogenesis, fatty acid synthesis, cholesterol synthesis)⁵⁰. As shown in Table 3, berberine shows medium combining capacity for docking all 18 targets and has an analogous binding energy with clinical drugs with the same targets. Therefore, berberine can efficiently act on the 18 targets, and it shows the identical combining capacities comparing with the clinical drugs. To investigate drug interactions in the same target, the docking results of AutoDock Vina were opened in AutoDockTools (ADT) with the conformation of minimum binding energy, which is the most stable conformation. The most stable conformations of all drugs targeting on AR, PGR and NR3C1 bonded target in one identical active pocket (Fig. 3). As a result of the existence

Figure 3. Drugs dock in the same site in targets. (A) Docking site between AR and drugs. (B) Docking site between PGR and drugs. (C) Docking site between NR3C1 and drugs.

PDB ID	Protein name	GENE name	Fit score	Source
1RY0	Aldo-keto reductase family 1 member C3	AKR1C3	3.783	PharmMapper
2AUH	Insulin receptor	INSR	3.771	PharmMapper
1KAV	Tyrosine-protein phosphatase non-receptor type 1	PTPN1	3.759	PharmMapper
1ERE	Estrogen receptor	ESR1	3.756	PharmMapper TCMSP
1GS4	Androgen receptor	AR	3.432	PharmMapper TCMSP
1P93	Glucocorticoid receptor	NR3C1	3.397	PharmMapper
2ZB0	Mitogen-activated protein kinase 14	MAPK14	3.393	PharmMapper
2ACL	Retinoic acid receptor RXR-alpha	RARA	3.389	PharmMapper
2J4A	Thyroid hormone receptor beta	THRB	3.316	PharmMapper
3EY4	Corticosteroid 11-beta-dehydrogenase isozyme 1	HSD11B1	3.261	PharmMapper
1BOA	Methionine aminopeptidase 2	METAP2	3.207	PharmMapper
1E3K	Progesterone receptor	PGR	3.071	PharmMapper
2FJP	Dipeptidyl peptidase 4	DPP4	3.009	PharmMapper
1EXA	Retinoic acid receptor gamma	RARG	2.955	PharmMapper
4GBR	Beta-2 adrenergic receptor	ADRB2		TCMSP

Table 2. The potential targets of berberine.

of competitive binding on the same active site, we speculate that these drugs trend to show competitive effects in these targets which probably could weaken target toleration to enhance drug effect in a long-time therapy and alleviate adverse drug reactions. By contrast the most stable conformations of those drugs that targeted the ESR1 and DPP4 bonded targets were all drugs acting on ESR1 and DPP4 were found in different active pockets (Fig. 4), so these drugs show a synergic effect in these targets.

Drug-target network. To determine the target distribution of drugs, drug-target network was constructed based on all drugs including berberine and their acting targets. As shown in Fig. 5, the drug-target network contains 53 nodes (31 drugs and 22 targets) and 73 edges. Berberine has the highest degree and betweenness centrality of 15 and 0.5, respectively, thereby indicating that berberine has the most important position in the network. The degrees of AR, 3-oxo-5-alpha-steroid 4-dehydrogenase 1 (SRD5A1), ESR1 and PGR are 10, 8, 8 and 8 respectively, which indicate that shows those drugs affecting hormone receptors are commonly used in clinical applications.

After combining the molecular docking results, we conjectured that berberine probably benefit PCOS patients around the center mechanism by activating AMPKs and MAPKs, and play its role for PCOS with all three phenotypes: activating ESR1 and PGR, suppressing AR, AKR1C3 and retinoic acid receptors to reduce androgen level of ovarian and plasma; activating INSR, THRB and PTPN1, inhibiting DPP4 to compete insulin resistance; activating NR3C1, THRB, PTPN1, inhibiting HSD11B1 and METAP2 to reduce body weight. Comparing with clinical drugs, berberine is likely to act on multiple targets and phenotypes in treating PCOS. As using combination drug therapy of berberine and other drugs, berberine could help clinical drugs access better efficacy by expressing synergy on the same target and acting on other targets of the disease network. In the meantime berberine seemingly plays a role of reducing the side effects by the competition on the same target, such as competitively antagonizing AR to lower teratogenic effect of antiandrogens.

Conclusion

PCOS is a chaotic disease with multiple factors and various clinical manifestations, so we probably need multi-target drug or multi-drug combination against PCOS. The modulation of a single drug target can be therapeutically insufficient, particularly in complex neuropsychiatric conditions, infectious diseases and cancers. Instead, it is frequently necessary for a drug to simultaneously engage two or more targets for therapeutic efficacy⁵¹. Despite its low bioavailability, berberine is a promising polypharmacological drug for PCOS as established by potential targets distribution and several studies in humans. The bioavailability of berberine may be increased

Protein name	Drug name	Binding Energy (kcal/mol)
Androgen receptor	Berberine	−8.6
	Chlormadinone acetate	−8.4
	Cyproterone acetate	−8.2
	Dienogest	−7.8
	Drospirenone	−8.7
	Flutamide	−8
	Gestodene	−8.5
	Ketoconazole	−7.4
	Levonorgestrel	−8.5
	Spironolactone	−7.6
Estrogen receptor	Berberine	−7.3
	Clomifene	−5.7
	Desogestrel	−6.9
	Estradiol	−7.8
	Levonorgestrel	−6.7
	Medroxyprogesterone Acetate	−6.7
	Norgestimate	−7.3
	Progesterone	−7
Progesterone receptor	Berberine	−9.7
	Desogestrel	−7.6
	Drospirenone	−11.9
	Levonorgestrel	−8.7
	Medroxyprogesterone Acetate	−9.5
	Norgestimate	−10
	Progesterone	−10.1
	Spironolactone	−8.6
Glucocorticoid receptor	Berberine	−10
	Dexamethasone	−8.4
	Spironolactone	−8.7
Dipeptidyl peptidase 4	Atorvastatin	−7.9
	Berberine	−8.6
Tyrosine-protein phosphatase non-receptor type 1	Berberine	−7.1
Retinoic acid receptor RXR-alpha	Berberine	−7.7
Retinoic acid receptor gamma	Berberine	−7
Thyroid hormone receptor beta	Berberine	−7.9
Beta-2 adrenergic receptor	Berberine	−7.3
Aldo-keto reductase family 1 member C3	Berberine	−7.6
Corticosteroid 11-beta-dehydrogenase isozyme 1	Berberine	−8.2
Insulin receptor	Berberine	−8.6
Mitogen-activated protein kinase 14	Berberine	−7.7
Methionine aminopeptidase 2	Berberine	−7.2
5'-AMP-activated protein kinase subunit alpha −1	Berberine	−7.3
5'-AMP-activated protein kinase subunit alpha −2	Berberine	−7.0
5'-AMP-activated protein kinase subunit beta −1	Berberine	−8.8

Table 3. The results of molecular docking.

through co-administration with absorption enhancers and development of berberine analogues or derivatives. Once berberine is administered concurrently with other drugs, clinical dose adjustment based on drug monitoring is recommended because of potential interactions between drugs.

Materials and Methods

Our protocol processed with four main strategies: (1) finding candidate targets related to PCOS and known targets of clinical drugs; (2) finding potential candidate targets of berberine related to PCOS; (3) constructing pathway-target network and drug-targets network, then analyzing these networks; (4) conducting molecular docking and analyzing docking results.

Finding candidate targets of PCOS and known drug targets. The mechanism of PCOS is undefined, so we searched potential candidate targets with searching keywords of hyperandrogenemia, hirsutism,

Figure 4. Drugs dock in the different sites in targets. (A) Docking site between ESR1 and drugs. (B) Docking site between DPP4 and drugs.

Figure 5. Target-pathway network. The drug-target network was constructed by linking the drugs and targets. The nodes represent drugs (yellow ellipses) and targets (green round rectangles).

acne, alopecia, menstrual disease, infertility, insulin resistance and obesity which are main phenotypic features of PCOS from TTD (<http://bidd.nus.edu.sg/group/ttd/>)⁵², PharmGkb (www.pharmgkb.org/)⁵³ and OMIM (<http://www.omim.org/>)⁵⁴ database. The clinical drugs were collected by Endocrine Society's practice guidelines for the diagnosis and treatment of PCOS⁵⁵ and literatures searching. Then the targets of these drugs were searched from DrugBank (<http://www.drugbank.ca/>)⁵⁶.

Finding potential targets of berberine. The spatial structure of berberine was downloaded from Pubchem compound database⁵⁷(Compound ID: 2353) with SDF format. The berberine structure then was optimized by assigning Gasteiger partial charges with AMBER ff14SB force field using Chimera 1.10.2 (Fig. 6). The potential targets of berberine were predicted by PharmMapper and TCMSP Database respectively.

Figure 6. The structure of berberine molecule with added Gasteiger partial charges using Chimera 1.10.2.

PharmMapper (<http://lilab.ecust.edu.cn/pharmmapper/index.php>)⁵⁸ is a web-based tool designed to predict potential drug target candidates for any given small molecule via a ‘reverse’ pharmacophore mapping approach. The model is supported by a large repertoire of pharmacophore database composed of more than 7,000 receptor-based pharmacophore models extracted from Target-Bank, DrugBank, BindingDB and PDTD. It predicts the best mapping poses for a given query molecule against all the pharmacophore models using ligand-protein reverse docking approach. The result lists the topN best-fitted hits with their respective aligned poses and target annotations. In this work, the optimized structure of berberine was submitted to PharmMapper for prediction of proteins with three dimensional structures in the Protein databank and the target set is just limited to the human targets (2241). The maximum number of reserved matched targets is defined as 300 and all parameters were kept as default.

TCMSP (<http://lsp.nwsuaf.edu.cn/tcmsp.php>) is a database of systems pharmacology for drug discovery from herbal medicines⁵⁹. The SysDT model was used to predict the potential targets of a compound in TCMSP. SysDT shows impressive performance of prediction for drug-target interactions, with a concordance of 82.83%, a sensitivity of 81.33%, and a specificity of 93.62%, respectively.

Constructing pathway-target network and drug-targets network. The DAVID⁶⁰ database was used to elucidate the function of potential candidate target proteins related to PCOS in the KEGG biological pathway. To make a deep exploring of the action mechanism of PCOS, the drug-target (D-T) network and pathway-target (P-T) network were constructed by Cytoscape 3.2.2⁶¹, and the key topological parameter degree and betweenness centrality were analyzed. The degree of a node characters as the number of edges associated with it and the betweenness centrality is equal to the number of shortest paths from all vertices to all others that pass through that node, indicating the importance of the node in a network.

Molecular docking. To validate the drug-target associations, the molecular docking simulation was further performed on each drug docking with their targets. All drug molecules including berberine were downloaded from Pubchem compound database and transformed to PDB file using Chimera (version 1.10.2). The protein structures of candidate targets were downloaded from RCSB Protein Data Bank (<http://www.rcsb.org/pdb>) and all protein files were opened with ADT (version 1.5.6) that is the free GUI for AutoDock. Water molecules in each file were deleted and polar hydrogen atoms were added, then wrote to a PDBQT file respectively. We selected the intersection of PCOS potential candidate targets and drugs targets for further research. For validating the interaction and observing the docking sites between drugs and targets, molecular docking was done by an open-source program named AutoDock Vina⁶². The docking results were observed with ADT.

References

1. Balen, A. Pathogenesis of polycystic ovary syndrome—the enigma unravels? *Lancet* **354**, 966–967 (1999).
2. Legro, R. S. Polycystic ovary syndrome: current and future treatment paradigms. *Am J Obstet Gynecol* **179**, s101–s108 (1998).
3. Norman, R. J., Dewailly, D., Legro, R. S. & Hickey, T. E. Polycystic ovary syndrome. *Lancet* **370**, 685–697 (2007).
4. Moran, C. *et al.* Prevalence of polycystic ovary syndrome and related disorders in mexican women. *Gynecol Obstet Invest* **69**, 274–280 (2010).
5. Sanchon, R. *et al.* Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors. *Hum Reprod* **27**, 1209–1216 (2012).
6. Legro, R. S. *et al.* Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* **98**, 4565–4592 (2013).
7. Rocca, M. L. *et al.* Polycystic ovary syndrome: chemical pharmacotherapy. *Expert Opin Pharmacother* **16**, 1369–1393 (2015).
8. Azziz, R. *et al.* Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. *J Clin Endocrinol Metab* **91**, 4237–4245 (2006).
9. Carmina, E. *et al.* Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. *J Clin Endocrinol Metab* **92**, 2500–2505 (2007).
10. Borruel, S. *et al.* Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS). *J Clin Endocrinol Metab* **98**, 1254–1263 (2013).
11. Pauli, J. M., Raja-Khan, N., Wu, X. & Legro, R. S. Current perspectives of insulin resistance and polycystic ovary syndrome. *Diabet Med* **28**, 1445–1454 (2011).

12. Gambineri, A., Pelusi, C., Vicennati, V., Pagotto, U. & Pasquali, R. Obesity and the polycystic ovary syndrome. *Int J Obes Relat Metab Disord* **26**, 883–896 (2002).
13. Escobar-Morreale, H. F. & San Millan, J. L. Abdominal adiposity and the polycystic ovary syndrome. *Trends Endocrinol Metab* **18**, 266–272 (2007).
14. Moran, L. J., Hutchison, S. K., Norman, R. J. & Teede, H. J. Lifestyle changes in women with polycystic ovary syndrome. *Cochrane Database Syst Rev* **7**, CD007506 (2011).
15. Imanshahidi, M. & Hosseinzadeh, H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. *Phytother Res* **22**, 999–1012 (2008).
16. Wu, X. Theca insulin resistance: dexamethasone induction and berberine intervention. *Fertil Steril* **94**, S197 (2010).
17. Zhao, L. *et al.* Berberine reduces insulin resistance induced by dexamethasone in theca cells *in vitro*. *Fertil Steril* **95**, 461–463 (2011).
18. Wei, W. *et al.* A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. *Eur J Endocrinol* **166**, 99–105 (2012).
19. Li, Y. *et al.* Letrozole, berberine, or their combination for anovulatory infertility in women with polycystic ovary syndrome: study design of a double-blind randomised controlled trial. *BMJ open* **3**, e003934 (2013).
20. An, Y. *et al.* The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. *Clin Endocrinol* **80**, 425–431 (2014).
21. Li, Y. *et al.* Effect of berberine on insulin resistance in women with polycystic ovary syndrome: study protocol for a randomized multicenter controlled trial. *Trials* **14**, 226 (2013).
22. Li, L. *et al.* A Single Arm Pilot Study of Effects of Berberine on the Menstrual Pattern, Ovulation Rate, Hormonal and Metabolic Profiles in Anovulatory Chinese Women with Polycystic Ovary Syndrome. *PLoS one* **10**, e0144072 (2015).
23. Kwon, M., Choi, Y. A., Choi, M.-K. & Song, I.-S. Organic cation transporter-mediated drug–drug interaction potential between berberine and metformin. *Arch Pharm Res* **38**, 849–856 (2015).
24. Colombo, D., Lunardon, L. & Bellia, G. Cyclosporine and herbal supplement interactions. *J Toxicol* **2014**, 145325 (2014).
25. Hou, Q., Han, W. & Fu, X. Pharmacokinetic interaction between tacrolimus and berberine in a child with idiopathic nephrotic syndrome. *Eur J Clin Pharmacol* **69**, 1861–1862 (2013).
26. Wu, X.-K. *et al.* Letrozole, berberine, or a combination for infertility in Chinese women with polycystic ovary syndrome: a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet* **386**, S70 (2015).
27. Pirillo, A. & Catapano, A. L. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From *in vitro* evidence to clinical studies. *Atherosclerosis* **243**, 449–461 (2015).
28. Sorger, P. K. *et al.* In An NIH white paper by the QSP workshop group. 1–48 (NIH Bethesda, 2011).
29. Rognan, D. Structure-based approaches to target fishing and ligand profiling. *Mol Inform* **29**, 176–187 (2010).
30. Schneider, G. *et al.* Voyages to the (un) known: adaptive design of bioactive compounds. *Trends Biotechnol* **27**, 18–26 (2009).
31. Li, J., Zhao, P., Li, Y., Tian, Y. & Wang, Y. Systems pharmacology-based dissection of mechanisms of Chinese medicinal formula Bufei Yishen as an effective treatment for chronic obstructive pulmonary disease. *Sci Rep* **5**, 15290 (2015).
32. Nie, W., Lv, Y., Yan, L., Chen, X. & Lv, H. Prediction and Characterisation of the System Effects of Aristolochic Acid: A Novel Joint Network Analysis towards Therapeutic and Toxicological Mechanisms. *Sci Rep* **5**, 17646 (2015).
33. Bellver, J. *et al.* Endometrial gene expression in the window of implantation is altered in obese women especially in association with polycystic ovary syndrome. *Fertil Steril* **95**, 2335–2341, e2338 (2011).
34. Whitmarsh, A. & Davis, R. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. *J Mol Med* **74**, 589–607 (1996).
35. Nelson-Degrave, V. L. *et al.* Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome. *Mol Endocrinol* **19**, 379–390 (2005).
36. Diamanti-Kandarakis, E. & Dunaif, A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. *Endocr Rev* **33**, 981–1030 (2012).
37. Bindea, G. *et al.* ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. *Bioinformatics* **25**, 1091–1093 (2009).
38. Vrbikova, J. & Cibula, D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. *Hum Reprod Update* **11**, 277–291 (2005).
39. De Leo, V. *et al.* Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome. *Fertil Steril* **88**, 113–117 (2007).
40. Pasquali, R. & Gambineri, A. THERAPY OF ENDOCRINE DISEASE: Treatment of hirsutism in the polycystic ovary syndrome. *Eur J Endocrinol* **170**, R75–R90 (2014).
41. Raval, A. D., Hunter, T., Stuckey, B. & Hart, R. J. Statins for women with polycystic ovary syndrome not actively trying to conceive. *Cochrane Database Syst Rev* **10**, CD008565 (2011).
42. Sirmans, S. M. & Pate, K. A. Epidemiology, diagnosis, and management of polycystic ovary syndrome. *Clin Epidemiol* **6**, 1 (2014).
43. Udhane, S. S., Pandey, A. V., Hofer, G., Mullis, P. E. & Flück, C. E. Retinoic acid receptor beta and angiotensin-like protein 1 are involved in the regulation of human androgen biosynthesis. *Sci Rep* **5**, 10132 (2015).
44. Davidson, J. A. The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes. *Endocr Pract* **19**, 1050 (2013).
45. Gambineri, A. *et al.* A combination of polymorphisms in HSD11B1 associates with *in vivo* 11 β -HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome. *Eur J Endocrinol* **165**, 283–292 (2011).
46. Hughes, T. *et al.* Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. *Obesity* **21**, 1782–1788 (2013).
47. Spencer-Jones, N. J. *et al.* Protein tyrosine phosphatase-1B gene PTPN1: selection of tagging single nucleotide polymorphisms and association with body fat, insulin sensitivity, and the metabolic syndrome in a normal female population. *Diabetes* **54**, 3296–3304 (2005).
48. Baxter, J. D. & Webb, P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. *Nat Rev Drug Discov* **8**, 308–320 (2009).
49. Ishiyama-Shigemoto, S., Yamada, K., Yuan, X., Ichikawa, F. & Nonaka, K. Association of polymorphisms in the β 2-adrenergic receptor gene with obesity, hypertriglyceridaemia, and diabetes mellitus. *Diabetologia* **42**, 98–101 (1999).
50. Krishan, S., Richardson, D. R. & Sahni, S. Adenosine Monophosphate-Activated Kinase and Its Key Role in Catabolism: Structure, Regulation, Biological Activity, and Pharmacological Activation. *Mol Pharmacol* **87**, 363–377 (2015).
51. Besnard, J. *et al.* Automated design of ligands to polypharmacological profiles. *Nature* **492**, 215–220 (2012).
52. Yang, H. *et al.* Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information. *Nucleic acids res.* gkv1230 (2015).
53. Thorn, C. F., Klein, T. E. & Altman, R. B. Pharmacogenomics and bioinformatics: PharmGKB. *Pharmacogenomics* **11**, 501–505 (2010).
54. Hamosh, A., Scott, A. F., Amberger, J. S., Bocchini, C. A. & McKusick, V. A. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. *Nucleic Acids Res* **33**, D514–D517 (2005).
55. Legro, R. S. *et al.* Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* **98**, 4565–4592 (2013).

56. Wishart, D. S. *et al.* DrugBank: a comprehensive resource for in silico drug discovery and exploration. *Nucleic Acids Res* **34**, D668–D672 (2006).
57. Bolton, E. *et al.* PubChem3D: a new resource for scientists. *J Cheminform* **3**, 32 (2011).
58. Liu, X. *et al.* PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. *Nucleic Acids Res* **38**, W609–W614 (2010).
59. Ru, J. *et al.* TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. *J Cheminform* **6**, 13 (2014).
60. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* **4**, 44–57 (2008).
61. Shannon, P. *et al.* Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res* **13**, 2498–2504 (2003).
62. Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comput Chem* **31**, 455–461 (2010).

Acknowledgements

This work was supported by Major State Basic Research Development Program (973 Program) of China (2013CB531801).

Author Contributions

H.X.K. and Q.H.W. designed and conceived the experiments; Y.W., X.F. and J.X. collected the data and analyzed data. All authors read and approved the final version of manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Wang, Y. *et al.* Systems pharmacology to investigate the interaction of Berberine and other drugs in treating polycystic ovary syndrome. *Sci. Rep.* **6**, 28089; doi: 10.1038/srep28089 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>